Protective effect of herbal medicine Huangqi decoction against chronic cholestatic liver injury by inhibiting bile acid-stimulated inflammation in DDC-induced mice

被引：49

作者：

Li Wen-Kai ^{[1
]}

Wang Guo-Feng ^{[1
]}

Wang Tian-Ming ^{[1
]}

Li Yuan-Yuan ^{[1
]}

Li Yi-Fei ^{[1
]}

Lu Xin-Yi ^{[1
]}

Wang Ya-Hang ^{[1
]}

Zhang Hua ^{[2
]}

Liu Ping ^{[2
]}

Wu Jia-Sheng ^{[1
]}

Ma Yue-Ming ^{[1
,3
]}

机构：

[1] Shanghai Univ Tradit Chinese Med, Sch Pharm, Dept Pharmacol, 1200 Cailun Rd, Shanghai 201203, Peoples R China

[2] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Inst Liver Dis, Key Lab Liver & Kidney Dis,Minist Educ, 528 Zhangheng Rd, Shanghai 201204, Peoples R China

[3] Shanghai Univ Tradit Chinese Med, Shanghai Key Lab Compound Chinese Med, Shanghai 201203, Peoples R China

来源：

PHYTOMEDICINE | 2019年 / 62卷

基金：

中国国家自然科学基金;

关键词：

Bile acid; Cholestasis; Huangqi decoction; NF-kappa B; Nrf2; DDC; PRIMARY SCLEROSING CHOLANGITIS; NUCLEAR RECEPTORS; MOUSE MODEL; FIBROSIS; PROLIFERATION; ACTIVATION; SERUM; SAPONINS;

D O I：

10.1016/j.phymed.2019.152948

中图分类号：

Q94 [植物学];

学科分类号：

071001 ;

摘要：

Background: Huangqi decoction (HQD), a classic traditional herbal medicine, has been used for liver fibrosis, but its effect on intrahepatic chronic cholestatic liver injury remains unknown. Purpose: In the present study, we investigated the hepatoprotective effect of HQD and the underlying molecular mechanisms in 3, 5-diethoxycarbonyl-1, 4-dihydroxychollidine (DDC)-induced chronic cholestatic mice. Methods: The DDC-induced cholestatic mice were administrated HQD for 4 or 8 weeks. Serum biochemistry and morphology were investigated. The serum and liver bile acid (BA) levels were detected by ultra performance liquid chromatography-tandem mass spectrometry. The liver expression of BA metabolizing enzymes and transporters, and inflammatory and fibrotic markers was measured by real-time polymerase chain reaction, western blotting, and immunohistochemistry. Results: HQD treatment for 4 or 8 weeks ameliorated DDC-induced liver injury by improving impaired hepatic function and tissue damage. HQD treatment for 8 weeks further decreased the liver expression of cytokeratin 19, tumor growth factor (TGF)-beta, collagen I, and alpha-smooth muscle actin, and ameliorated ductular reaction and liver fibrosis. HQD markedly decreased the accumulation of serum and liver BA. The expression of BA-metabolizing enzymes, cytochrome P450 2b10 and UDP glucuronosyltransferase 1 A1, and multidrug resistance-associated protein 2, Mrp3, and Mrp4 involved in BA homeostasis was increased by 4 weeks of HQD treatment. The expression of BA uptake transporter Na+-taurocholate cotransporting polypeptide was decreased and that of Mrp4 was increased after 8 weeks of HQD treatment. Nuclear factor-E2-related factor-2 (Nrf2) was remarkably induced by HQD treatment. Additionally, HQD treatment for 8 weeks decreased the liver expression of inflammatory factors, interleukin (IL)-6, IL-beta, tumor necrosis factor-alpha, monocyte chemoattractant protein-1, and intracellular adhesion molecule-1. HQD suppressed the nuclear factor (NF)-kappa B pathway. Conclusion: HQD protected mice against chronic cholestatic liver injury and biliary fibrosis, which may be associated with the induction of the Nrf2 pathway and inhibition of the NF-kappa B pathway, ameliorating BA-stimulated inflammation.

引用

页数：12

共 44 条

[1] Population-Based Epidemiology, Malignancy Risk, and Outcome of Primary Sclerosing Cholangitis [J].

Boonstra, Kirsten ;

Weersma, Rinse K. ;

van Erpecum, Karel J. ;

Rauws, Erik A. ;

Spanier, B. W. Marcel ;

Poen, Alexander C. ;

van Nieuwkerk, Karin M. ;

Drenth, Joost P. ;

Witteman, Ben J. ;

Tuynman, Hans A. ;

Naber, Anton H. ;

Kingma, Paul J. ;

van Buuren, Henk R. ;

van Hoek, Bart ;

Vleggaar, Frank P. ;

van Geloven, Nan ;

Beuers, Ulrich ;

Ponsioen, Cyriel Y. .

HEPATOLOGY, 2013, 58 (06) :2045-2055

[2] Activation of Interleukin-6/STAT3 in Rat Cholangiocyte Proliferation Induced by Lipopolysaccharide [J].

Chen, Li-Ping ;

Cai, Ming ;

Zhang, Qi-Hao ;

Li, Zhou- ;

Qian, Ye-Yong ;

Bai, Hong-Wei ;

Wei, Xing ;

Shi, Bing-Yi ;

Dong, Jia-Hong .

DIGESTIVE DISEASES AND SCIENCES, 2009, 54 (03) :547-554

[3]

Cheng Y., 2018, CHIN J INTEGR MED

[4]

Chiang John Y. L., 2018, Gene Expression, V18, P71, DOI 10.3727/105221618X15156018385515

[5] Bile Acid Metabolism and Signaling [J].

Chiang, John Y. L. .

COMPREHENSIVE PHYSIOLOGY, 2013, 3 (03) :1191-1212

[6] Ingredients of Huangqi decoction slow biliary fibrosis progression by inhibiting the activation of the transforming growth factor-beta signaling pathway [J].

Du, Jin-Xing ;

Sun, Ming-Yu ;

Du, Guang-Li ;

Li, Feng-Hua ;

Liu, Cheng ;

Mu, Yong-Ping ;

Chen, Gao-Feng ;

Long, Ai-Hua ;

Bian, Yan-Qin ;

Liu, Jia ;

Liu, Cheng-Hai ;

Hu, Yi-Yang ;

Xu, Lie-Ming ;

Liu, Ping .

BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2012, 12

[7]

DU Jin-Xing, 2010, Zhonghua Gan Zang Bing Za Zhi, V18, P13, DOI 10.3760/cma.j.issn.1007-3418.2010.01.004

[8] Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management [J].

Eaton, John E. ;

Talwalkar, Jayant A. ;

Lazaridis, Konstantinos N. ;

Gores, Gregory J. ;

Lindor, Keith D. .

GASTROENTEROLOGY, 2013, 145 (03) :521-536

[9] A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis [J].

Fickert, Peter ;

Stoeger, Ulrike ;

Marschall, Hanns-Ulrich ;

Weiglein, Andreas H. ;

Tsybrovskyy, Oleksiy ;

Jaeschke, Hartmut ;

Zatloukal, Kurt ;

Denk, Helmut ;

Trauner, Michael .

AMERICAN JOURNAL OF PATHOLOGY, 2007, 171 (02) :525-536

[10] Association between serum bile acid profiles and gestational diabetes mellitus: A targeted metabolomics study [J].

Gao, Jieying ;

Xu, Biao ;

Zhang, Xiaoqing ;

Cui, Yue ;

Deng, Linlin ;

Shi, Zhenghu ;

Shao, Yong ;

Ding, Min .

CLINICA CHIMICA ACTA, 2016, 459 :63-72

← 1 2 3 4 5 →